EP Wealth Advisors LLC Sells 553 Shares of Xencor, Inc. (NASDAQ:XNCR)

EP Wealth Advisors LLC trimmed its position in shares of Xencor, Inc. (NASDAQ:XNCR – Get Rating) by 4.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,000 shares of the biopharmaceutical company’s stock after selling 553 shares during the quarter. EP Wealth Advisors LLC’s holdings in Xencor were worth $338,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Quadrant Capital Group LLC boosted its position in Xencor by 364.8% during the 3rd quarter. Quadrant Capital Group LLC now owns 2,180 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 1,711 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Xencor by 203.0% during the first quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 3,005 shares during the last quarter. Virtus ETF Advisers LLC lifted its holdings in shares of Xencor by 12.9% during the second quarter. Virtus ETF Advisers LLC now owns 5,185 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 593 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Xencor by 63.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 6,546 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 2,536 shares during the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in shares of Xencor during the second quarter valued at approximately $177,000. 98.99% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on XNCR. Canaccord Genuity Group lowered their target price on shares of Xencor from $48.00 to $42.00 and set a “buy” rating for the company in a report on Friday, February 24th. SVB Leerink restated an “outperform” rating on shares of Xencor in a report on Thursday, February 23rd. Mizuho restated a “buy” rating and issued a $59.00 price objective on shares of Xencor in a report on Friday, February 10th. Cowen assumed coverage on shares of Xencor in a report on Tuesday, December 6th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Xencor from $37.00 to $42.00 and gave the stock an “overweight” rating in a report on Monday, February 13th. One analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average target price of $46.13.

Insider Buying and Selling

In other Xencor news, CEO Bassil I. Dahiyat sold 5,831 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $31.42, for a total value of $183,210.02. Following the transaction, the chief executive officer now directly owns 252,303 shares in the company, valued at approximately $7,927,360.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Xencor news, CEO Bassil I. Dahiyat sold 5,831 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $31.42, for a total value of $183,210.02. Following the completion of the sale, the chief executive officer now directly owns 252,303 shares in the company, valued at $7,927,360.26. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Celia Eckert sold 2,462 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $31.42, for a total transaction of $77,356.04. Following the completion of the transaction, the vice president now directly owns 37,687 shares of the company’s stock, valued at approximately $1,184,125.54. The disclosure for this sale can be found here. Insiders have sold 27,477 shares of company stock valued at $840,527 in the last ninety days. 4.23% of the stock is owned by company insiders.

Xencor Stock Down 1.0 %

Shares of Xencor stock opened at $28.05 on Friday. The company has a fifty day moving average of $31.82 and a 200 day moving average of $28.98. Xencor, Inc. has a fifty-two week low of $19.35 and a fifty-two week high of $38.20.

Xencor (NASDAQ:XNCR – Get Rating) last issued its earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.63. The company had revenue of $21.61 million during the quarter, compared to the consensus estimate of $19.24 million. Xencor had a negative net margin of 33.53% and a negative return on equity of 7.47%. Xencor’s quarterly revenue was down 86.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.21 EPS. On average, analysts anticipate that Xencor, Inc. will post -2.8 earnings per share for the current year.

Xencor Company Profile

(Get Rating)

Xencor, Inc is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.